The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile

Laboratory Investigation

Volumn 88, Issue 5, 2008, Pages 482-490

  Ma, Yue ^a   Visser, Lydia ^a   Blokzijl, Tjasso ^a   Harms, Geert ^a   Atayar, Çiǧdem ^a   Poppema, Sibrand ^a   Van Den Berg, Anke ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anergy; CD4+CD26 T cells; Hodgkin lymphoma; Quantitative RT PCR; Regulatory T cells

Indexed keywords

CD134 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5;

ADOLESCENT; ADULT; ARTICLE; CANCER RESEARCH; CD4 LYMPHOCYTE COUNT; CELL POPULATION; CELL SELECTION; CELL STIMULATION; CELL SUSPENSION; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO SELECTION; LYMPH NODE; LYMPH NODE CELL; MALE; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; T LYMPHOCYTE; TH1 CELL; TH2 CELL; UPREGULATION;

ADOLESCENT; ADULT; ANTIGENS, CD26; CD4-POSITIVE T-LYMPHOCYTES; CHILD; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IONOMYCIN; LYMPH NODES; MALE; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLEROSIS; STAINING AND LABELING; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TETRADECANOYLPHORBOL ACETATE;

EID: 42549166115     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.24     Document Type: Article

References (60)

1. Harris NL. Hodgkin's lymphomas: classification, diagnosis, and grading. Semin Hematol 1999;36:220-232.
2. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells: a possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999;154:1685-1691.
3. Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin's disease. Leuk Lymphoma 2000;38:363-371.
4. Peh SC, Kim LH, Poppema S. TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma. Am J Surg Pathol 2001;25:925-929.
5. Hedvat CV, Jaffe ES, Qin J, et al. Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays. Mod Pathol 2001;14:1270-1276.
6. Gruss HJ, Pinto A, Duyster J, et al. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997;18:156-163.
7. Atayar C, Poppema S, Visser L, et al. Cytokine gene expression profile distinguishes CD4+/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma from their tonsillar counterparts. J Pathol 2006;208:423-430.
8. Poppema S, Lai R, Visser L, et al. CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets. Leuk Lymphoma 1996;20:217-222.
9. Poppema S. Immunology of Hodgkin's disease. Baillieres Clin Haematol 1996;9:447-457.
10. Poppema S. The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. Am J Pathol 1989;135:351-357.
11. Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol Today 1994;15:180-184.
12. Fox DA, Hussey RE, Fitzgerald KA, et al. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol 1984;133:1250-1256.
13. Mattern T, Scholz W, Feller AC, et al. Expression of CD26 (dipeptidyl peptidase IV) on resting and activated human T-lymphocytes. Scand J Immunol 1991;33:737-748.
14. Poppema S, Potters M, Visser L, et al. Immune escape mechanisms in Hodgkin's disease. Ann Oncol 1998;9:S21-S24.
15. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755-1762.
16. Ishida T, Ishii T, Inagaki A, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006;66:5716-5722.
17. Baráth S, Aleksza M, Keresztes K, et al. Immunoregulatory T cells in the peripheral blood of patients with Hodgkin's lymphoma. Acta Haematol 2006;116:181-185.
18. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-562.
19. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-4297.
20. Malec M, Söderqvist M, Sirsjö A, et al. Real-time polymerase chain reaction determination of cytokine mRNA expression profiles in Hodgkin's lymphoma. Haematologica 2004;89:679-685.
21. Atayar C, Poppema S, Blokzijl T, et al. Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas. Am J Pathol 2005;166:127-134.
22. Hegen M. CD26 workshop panel report. In: Kishimoto T, Kikutani H, von dem Borne AEGKr et al. (eds). Leukocyte Typing VI. White Cell Differentiation Antigens. Garland Publishing Inc.: New York, 1997, pp 478-481.
23. Gruss HJ, Brach MA, Drexler HG, et al. Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res 1992;52:3353-3360.
24. Gruss HJ, Herrmann F, Drexler HG. Hodgkin's disease: a cytokine-producing tumor - a review. Crit Rev Oncog 1994;5:473-538.
25. Kadin ME. Pathology of Hodgkin's disease. Curr Opin Oncol 1994;6:456-463.
26. Teruya-Feldstein J, Jaffe ES, Burd PR, et al. Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood 1999;93:2463-2470.
27. Buri C, Körner M, Schärli P, et al. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease. Blood 2001;97:1543-1548.
28. Daugherty BL, Siciliano SJ, DeMartino JA, et al. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996;183:2349-2354.
29. Combadiere C, Ahuja SK, Murphy PM. Cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem 1995;270:16491-16494.
30. Maggio EM, van den Berg A, Visser L, et al. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. Int J Cancer 2002;99:665-672.
31. Fischer M, Juremalm M, Olsson N, et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003;107:197-201.
32. Vermeer MH, Dukers DF, ten Berge RL, et al. Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease. Mod Pathol 2002;15:838-844.
33. Mariani M, Lang R, Binda E, et al. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur J Immunol 2004;34:231-240.
34. Mullen AC, High FA, Hutchins AS, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 2001;292:1907-1910.
35. Gubler U, Chua AO, Schoenhaut DS, et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991;88:4143-4147.
36. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991;146: 3074-3081.
37. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997;89:587-596.
38. Cosmi L, Annunziato F, Galli MIG, et al. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur J Immunol 2000;30: 2972-2979.
39. Nagata K, Tanaka K, Ogawa K, et al. Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol 1999;162:1278-1286.
40. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2:816-822.
41. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32.
42. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
43. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
44. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
45. Kronenberg M, Rudensky A. Regulation of immunity by self-reactive T cells. Nature 2005;435:598-604.
46. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192: 303-310.
47. Takeda I, Ine S, Killeen N, et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 2004;172:3580-3589.
48. Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ regulatory T cells. J Exp Med 2001;194:847-854.
49. Lee I, Wang L, Wells AD, et al. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 2005;201:1037-1044.
50. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761.
51. Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-612.
52. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-1132.
53. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-1141.
54. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-[beta]1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 2007;26:579-591.
55. Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007;178:6730-6733.
56. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998;95:1178-1183.
57. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-1064.
58. Dieckmann D, Plottner H, Berchtold S, et al. Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood. J Exp Med 2001;193:1303-1310.
59. Groux H, Bigler M, de Vries JE, et al. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996;184:19-29.
60. Buer J, Lanoue A, Franzke A, et al. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class IIrestricted T cells anergized in vivo. J Exp Med 1998;187:177-183.